DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Tacrolimus Ointment Interest (PROTOPIC �) in the Maintenance Treatment of Severe Seborrheic Dermatitis

Information source: University Hospital, Rouen
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Severe Seborrheic Dermatitis

Intervention: Protopic (R) (Drug); Mycoster (R) (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: University Hospital, Rouen

Official(s) and/or principal investigator(s):
Pascal JOLY, Professor, Study Director, Affiliation: University Hospital, Rouen

Overall contact:
Pascal JOLY, Professor, Phone: 2 32 88 68 41, Ext: +33, Email: pascal.joly@chu-rouen.fr

Summary

Seborrheic dermatitis is a chronic inflammatory dermatological disease, evolving by relapses, affecting mainly the face and scalp. It would be important to have a maintenance treatment for severe forms of seborrheic dermatitis witch is both effective and relatively well tolerated to reduce the frequency of relapses, prolong remissions obtained after attack treatment and reduce the use of topical steroids.

Clinical Details

Official title: Phase 3 : Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis on Adult Face

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: duration of the maintenance of complete or almost complete clinical remission

Secondary outcome:

Tolerance of 2 treatments

Number of Relapses

Cumulative amount of corticosteroids applied

quality of life of patients

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- in Phase 1: Attack Treatment (open)

1. over the age of eighteen patient, 2. Seborrheic dermatitis Severe, 3. participation with an informed consent, 4. Women of childbearing age in effective contraception for the duration of the study or postmenopausal women.

- in Phase 2: Phase 2: "Randomization" (blind)

1. Patient achieved a complete or almost complete clinical remission after the initial treatment, 2. known immunodeficiency (HIV patient receiving chemotherapy) or immunosuppressive therapy or biotherapy, 3. patient taking regular systemic corticosteroids at a dose> 20 mg / day 4. erythematous lesions with topography other than the face and evocative scalp psoriasis (elbows, knees ...), by referring to the possibility that the facial lesions correspond to lesions sebopsoriasis, 5. woman pregnant, nursing or in childbearing potential without effective contraception, 6. man wishing to have a child during the study period, 7. Ultra Violet (UV) phototherapy or usual realization of UV sessions aesthetic purposes, 8. Seborrheic dermatitis symptomatic of an underlying disease known or revealing 9. history of cancer or lymphoma, 10. progressive cancer or lymphoma, 11. Seborrheic dermatitis exclusively affecting the scalp, 12. known allergy to one-component products study , 13. malnourished patient or sick history of chronic pancreatitis by a suspect to deficiency dermatitis, 14. participation in a clinical trial on the Seborrheic dermatitis in the previous 90 days, 15. patient with lesions considered potentially malignant or pre-cancerous, 16. patient with abnormal skin barrier. Exclusion Criteria:

- in Phase 1: Attack Treatment (open)

1) Patient had already been treated with Protopic ® for Seborrheic Dermatitis,

- Phase 2: "Randomization" (blind) 1) Patient with no complete or almost complete

clinical remission after the initial treatment,

Locations and Contacts

Pascal JOLY, Professor, Phone: 2 32 88 68 41, Ext: +33, Email: pascal.joly@chu-rouen.fr

Rouen University Hospital, Rouen 76031, France; Recruiting
Pascal Joly, Professor, Phone: 2 32 88 68 41, Ext: +33, Email: pascal.joly@chu-rouen.fr
philippe Musette, professor, Phone: 2 32 88 68 41, Ext: +33, Email: philippe.musette@chu-rouen.fr
Pascal JOLY, Pr, Principal Investigator
Additional Information

Starting date: January 2014
Last updated: March 23, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017